Perfil de judicialização no Rio Grande do Norte: impacto da insulina nos custos à saúde
Introduction: Access to medicines represents the principle of public policies established by the components of Pharmaceutical Services. Still, the judicialization of medicines is growing, given the inability of the system or even lack of information on access. This study, therefore, aimed to anal...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | bachelorThesis |
| Idioma: | pt_BR |
| Publicado em: |
Universidade Federal do Rio Grande do Norte
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/handle/123456789/35756 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| Resumo: | Introduction: Access to medicines represents the principle of public policies
established by the components of Pharmaceutical Services. Still, the judicialization of
medicines is growing, given the inability of the system or even lack of information on access.
This study, therefore, aimed to analyze the different requests via court decisions for treatment
alternatives to patients with diabetes in the state of Rio Grande do Norte between 2013 and
2017. Methodology: This is a cross-sectional view of a larger exploratory study, CAAE
79763617.4.0000.5292. Results: A total of 987 patients requested medication through the
judicial route, 108 of them eligible for this study. Of these, 55.45% reside in the Central
Potiguar mesoregion and 27.32% of the lawsuits took place in 2015. The most requested
judicialized medications were insulin glargine (35.58%), insulin lispro (14.42%) and insulin
aspart (8.17%). In addition to the drugs present in RENAME: glibenclamide, gliclazide, NPH
insulin, regular insulin and metformin, representing a total of 9.61% of requests. Following the
ICD-10 category, endocrine, nutritional and metabolic diseases accounted for 94.74% of cases
involving judicialization of antidiabetic drugs. Conclusion: The study concluded that there was
an increase in lawsuits by the defense system, in addition to increased requests for insulin
glargine and number of cases requested from patients in the central mesoregion. |
|---|